Skip to main content
    A

    Amgen Inc (AMGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $462.32
    -3.35 (-0.72%)

    Market Cap: $251.89B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amgen Inc (AMGN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Amgen reported revenue of $36.75B for the fiscal year ended Dec 31, 2025, up 10.0% from the year before. That year, net income was $7.71B with a net margin of 21.0%, operating cash flow was $9.96B and free cash flow was $8.10B. The quarter ended Sep 30, 2026 had revenue of $10.37B and net income of $3.86B.

    Revenue and Margins

    The operating margin was 24.7% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $22.99B, a compound annual rate of 5.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$36.75B+10.0%67.2%24.7%21.0%
    Dec 2024$33.42B+18.6%61.5%21.7%12.2%
    Dec 2023$28.19B+7.1%70.0%28.0%23.8%
    Dec 2022$26.32B+1.3%75.7%36.3%24.9%
    Dec 2021$25.98B+2.2%75.2%29.4%22.7%
    Dec 2020$25.42B+8.8%75.8%35.9%28.6%
    Dec 2019$23.36B-1.6%81.4%41.4%33.6%
    Dec 2018$23.75B+3.9%82.7%43.2%35.3%
    Dec 2017$22.85B-0.6%82.2%43.6%8.7%
    Dec 2016$22.99BN/A81.9%42.6%33.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 88.5% from the year before. In the quarter ended Sep 2026, net income rose 19.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$36.75B$33.42B$28.19B$26.32B$25.98B$25.42B$23.36B$23.75B$22.85B$22.99B
    Cost of revenue$12.04B$12.86B$8.45B$6.41B$6.45B$6.16B$4.36B$4.10B$4.07B$4.16B
    Gross profit$24.71B$20.57B$19.74B$19.92B$19.52B$19.27B$19.01B$19.65B$18.78B$18.83B
    Research and development$7.27B$5.96B$4.78B$4.43B$6.32B$4.21B$4.12B$3.74B$3.56B$3.84B
    Operating income$9.08B$7.26B$7.90B$9.57B$7.64B$9.14B$9.67B$10.26B$9.97B$9.79B
    Net income$7.71B$4.09B$6.72B$6.55B$5.89B$7.26B$7.84B$8.39B$1.98B$7.72B
    EBITDA$16.90B$13.36B$14.80B$12.17B$11.30B$13.00B$12.63B$12.88B$12.86B$12.53B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$10.37B$10.05B$8.62B$9.87B$9.56B$9.18B$8.15B$9.09B$8.50B$8.39B$7.45B$8.20B
    Gross profit$7.58B$7.24B$5.87B$6.89B$6.47B$6.17B$5.18B$5.97B$5.19B$5.15B$4.25B$5.08B
    Operating income$3.71B$3.51B$2.67B$2.72B$2.53B$2.66B$1.18B$2.31B$2.05B$1.91B$991.00M$1.27B
    Net income$3.86B$2.38B$1.82B$1.33B$3.22B$1.43B$1.73B$627.00M$2.83B$746.00M-$113.00M$767.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $54.60B exceeded cash and equivalents by $45.48B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$90.59B$91.84B$97.15B$65.12B$61.16B$62.95B$59.71B$66.42B$79.95B$77.63B
    Current assets$29.06B$29.03B$30.33B$22.19B$19.39B$21.14B$18.44B$37.62B$49.48B$46.01B
    Cash and equivalents$9.13B$11.97B$10.94B$7.63B$7.99B$6.27B$6.04B$6.95B$3.80B$3.24B
    Total liabilities$81.93B$85.96B$90.92B$61.46B$54.47B$53.54B$50.03B$53.92B$54.71B$47.75B
    Short-term debt$4.60B$3.55B$1.44B$1.59B$87.00M$91.00M$2.95B$4.42B$1.15B$4.40B
    Long-term debt$50.01B$56.55B$63.17B$37.35B$33.22B$32.90B$26.95B$29.51B$34.19B$30.19B
    Shareholder equity$8.66B$5.88B$6.23B$3.66B$6.70B$9.41B$9.67B$12.50B$25.24B$29.88B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$96.05B$95.64B$92.50B$90.59B$90.14B$87.90B$89.37B$91.84B$90.88B$90.91B$92.98B$97.15B
    Total liabilities$81.70B$83.95B$83.31B$81.93B$80.52B$80.47B$83.16B$85.96B$83.36B$84.98B$87.96B$90.92B
    Cash and equivalents$13.19B$13.99B$12.04B$9.13B$9.45B$8.03B$8.81B$11.97B$9.01B$9.30B$9.71B$10.94B
    Shareholder equity$14.35B$11.69B$9.19B$8.66B$9.62B$7.43B$6.21B$5.88B$7.53B$5.92B$5.02B$6.23B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 81.3% of operating cash flow. Dividends came to 63.2% of it, with no share repurchases.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$9.96B$11.49B$8.47B$9.72B$9.26B$10.50B$9.15B$11.30B$11.18B$10.35B
    Capital expenditures$1.86B$1.10B$1.11B$936.00M$880.00M$608.00M$618.00M$738.00M$664.00M$738.00M
    Free cash flow$8.10B$10.39B$7.36B$8.79B$8.38B$9.89B$8.53B$10.56B$10.51B$9.62B
    Dividends paid$5.12B$4.83B$4.56B$4.20B$4.01B$3.75B$3.51B$3.51B$3.37B$3.00B
    Share repurchases$0$200.00M$0$6.36B$4.97B$3.49B$7.70B$17.79B$3.16BN/A
    Investing cash flow-$1.94B-$1.05B-$26.20B-$6.04B$733.00M-$5.40B$5.71B$14.34B-$4.02B-$8.66B
    Financing cash flow-$10.86B-$9.41B$21.05B-$4.04B-$8.27B-$4.87B-$15.77B-$22.49B-$6.59B-$2.60B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$4.24B$4.00B$2.19B$1.60B$4.68B$2.28B$1.39B$4.77B$3.57B$2.46B$689.00M$538.00M
    Capital expenditures$587.00M$513.00M$712.00M$642.00M$436.00M$369.00M$411.00M$371.00M$257.00M$238.00M$230.00M$249.00M
    Free cash flow$3.65B$3.49B$1.48B$961.00M$4.25B$1.91B$980.00M$4.40B$3.31B$2.22B$459.00M$289.00M
    Last 12 quarters

    Frequently Asked Questions About AMGN

    What is Amgen's annual revenue?

    Amgen reported revenue of $36.75B for the fiscal year ended Dec 31, 2025.

    How fast is Amgen's revenue growing?

    Revenue was up 10.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 11.8%.

    Is Amgen profitable?

    Yes. Amgen reported net income of $7.71B for the fiscal year ended Dec 31, 2025, with a net margin of 21.0%.

    How much free cash flow does AMGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $9.96B minus capital expenditures of $1.86B produced free cash flow of $8.10B.

    How much debt does Amgen have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $50.01B, short-term debt of $4.60B and cash and equivalents of $9.13B.